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Chromatin accessibility landscape 
of articular knee cartilage reveals 
aberrant enhancer regulation in 
osteoarthritis
Ye Liu1,2,3, Jen-Chien Chang  1,2, Chung-Chau Hon  4,5, Naoshi Fukui6,7, Nobuho Tanaka6, 
Zhenya Zhang3, Ming Ta Michael Lee  8,9,10 & Aki Minoda  1,2
Osteoarthritis (OA) is a common joint disorder with increasing impact in an aging society. While 
genetic and transcriptomic analyses have revealed some genes and non-coding loci associated to OA, 
the pathogenesis remains incompletely understood. Chromatin profiling, which provides insight into 
gene regulation, has not been reported in OA mainly due to technical difficulties. Here, we employed 
Assay for Transposase-Accessible Chromatin with high throughput sequencing (ATAC-seq) to map 
the accessible chromatin landscape in articular knee cartilage of OA patients. We identified 109,215 
accessible chromatin regions for cartilages, of which 71% were annotated as enhancers. By overlaying 
them with genetic and DNA methylation data, we have determined potential OA-relevant enhancers 
and their putative target genes. Furthermore, through integration with RNA-seq data, we characterized 
genes that are altered both at epigenomic and transcriptomic levels in OA. These genes are enriched 
in pathways regulating ossification and mesenchymal stem cell (MSC) differentiation. Consistently, 
the differentially accessible regions in OA are enriched for MSC-specific enhancers and motifs of 
transcription factor families involved in osteoblast differentiation. In conclusion, we demonstrate how 
direct chromatin profiling of clinical tissues can provide comprehensive epigenetic information for a 
disease and suggest candidate genes and enhancers of translational potential.
Osteoarthritis (OA) is a degenerative joint disease1,2 that is one of the most common causes of chronic disability 
in the world3,4, of which the knee OA is the most common. Main features of OA include cartilage degradation, 
subchondral bone thickening, joint space narrowing and osteophytes formation5, resulting in stiffness, swell-
ing, and pain in the joint. Currently available treatments are either pain relief or joint function improvement by 
strengthening the supporting muscles. However, OA progression ultimately leads to costly total joint replacement 
surgery, making it a growing global health burden.
Although the causes of OA are not well understood, risk factors such as age, weight, gender, and genetic fac-
tors have been identified4. Several models for OA initiation, such as mechanical injury, inflammatory mediators 
from synovium, defects in metabolism and endochondral ossification, have been proposed to explain patho-
genesis of this disease6–12. To date, Genome-wide association studies (GWAS) have identified more than 20 loci 
to be associated with the risk of developing OA13. While next generation sequencing data is being generated to 
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discover rare variants with larger effect size, the identified variants are often located in the non-coding regions of 
the genome14, complicating the identification of the causal genes. Transcriptomic analyses of cartilage in diseased 
joints of OA patients (taken from replacement surgeries) provided an opportunity to pinpoint transcriptionally 
dysregulated genes and pathways relevant to OA15,16. However, such studies have yet to fully reveal the underlying 
molecular mechanism of how the transcription of these genes are dysregulated.
Recently, epigenetic tools have been applied to gain further insight into the pathogenesis of OA. There have 
been reports of DNA methylation status in cartilage of diseased joints, revealing epigenetic marks as poten-
tial mediators of OA genetic risk17–23. However, the change of gene expression is rarely associated with DNA 
methylation alterations at promoters16,24,25. Many of the identified differentially methylated sites fall in enhancer 
regions19,21–23, which are non-coding regulatory elements, disruption of which may lead to dysregulated transcrip-
tion, and many are cell type-specific26,27. Recent large-scale studies, such as FANTOM528, Roadmap Epigenomics 
Project29 and GTEx30 have enabled the prediction of regulatory networks between enhancers and their potential 
target genes (e.g. JEME31), which could be applied in a clinical context to explore the roles of enhancers in disease 
pathogenesis.
Here, we set out to investigate alterations of enhancers associated with OA by applying ATAC-seq32 on the 
knee joint cartilages from OA patients, using an optimized protocol for cartilage sample preparation. ATAC-seq 
maps the accessible chromatin regions, which are often regulatory regions such as promoters and enhancers that 
play roles in regulation of gene expression. By integrating our ATAC-seq data with the publicly available genetic, 
transcriptomic and epigenomic data, we identified dysregulated enhancers and their potential target genes. Our 
data highlights a number of OA risk loci and differentially methylated loci (DML) that potentially play roles in 
cartilage degradation during OA development.
Results
Mapping chromatin accessibility of chondrocytes in OA knee cartilages. To investigate chroma-
tin signatures in articular cartilage associated with OA, we performed ATAC-seq on the chondrocytes isolated 
from the knee joints of patients. We have previously shown that the oLT region (outer region of the lateral tibial 
plateau, representing the intact cartilage) is a good control for comparing the iMT region (inner region of medial 
tibial plateau, representing the damaged cartilage) as a model for OA disease progression16, and the transcriptome 
and methylome of this model have been characterized by us and the others24,25,33,34. In this study, we performed 
ATAC-seq on the chondrocytes isolated from oLT and iMT regions of 8 patients (Supplementary Figure S1a), 
generating 16 ATAC-seq libraries (pairs from 8 patients) on clinically relevant OA cartilage tissues (Fig. 1a).
Overall, the libraries are of high quality, showing two- to four-fold enrichment in the Roadmap DHS (DHS 
enrichment score, Methods), with no substantial difference between oLT and iMT libraries (Supplementary 
Table S2). In addition, the expected nucleosome banding patterns were observed in the fragment size distribution 
for both oLT and iMT libraries (Fig. 1b). When we applied nucleoATAC to infer genome-wide nucleosome occu-
pancy and positioning from ATAC-seq data35, we found similar aggregated signals around transcription start sites 
(TSS) for both oLT and iMT libraries, corresponding to −2, −1, +1, +2, +3 nucleosomes as well as nucleosome 
depletion region at upstream of TSS (Fig. 1c). Thus, we concluded that our ATAC-seq libraries had good and 
indistinguishable quality between oLT and iMT regions.
Figure 1. ATAC-seq of OA cartilage tissues. (a) Schematic diagram of the experimental flow. Chondrocyte 
from two regions of the articular cartilages were isolated for ATAC-seq. oLT (outer Libial Tibial): intact 
tissue. iMT (inner Medial Tibial): damaged tissue. (b) ATAC-seq sequencing fragment length distribution for 
pooled oLT (n = 8) and iMT (n = 8) libraries. The banding pattern, representing fragments from nucleosome 
free regions, mono-, di-, and tri-nucleosome, indicates a successful ATAC-seq experiment. (c) Normalized 
nucleoATAC signal aggregated over all genes shows distinct nucleosome positioning around transcription start 
sites (TSS). Positive and negative numbers indicate the TSS upstream and downstream nucleosomes.
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Accessible chromatin landscape highlights potential enhancers and their target genes relevant 
to OA. Based on the 16 ATAC-seq libraries, we identified a set of unified accessible chromatin regions across 
all samples (n = 109,215 robust peaks, Methods, Supplementary Table S3); 77,655 (71.1%) of which were anno-
tated as enhancers and 18,410 (16.9%) as promoters (Fig. 2a) based on Roadmap DHS annotations (Methods). 
To assess the relevance of these peaks to OA, we intersected these peaks against OA GWAS (Single Nucleotide 
Polymorphisms) SNPs and OA DML datasets. We found 149 peaks (31 promoters and 101 enhancers) overlap-
ping with OA-associated GWAS SNPs and 2,508 peaks (595 promoters and 1,715 enhancers) overlapping with 
OA DML. The fact that majority of these overlapping peaks are enhancers, along with the notion that many 
disease-associated noncoding variants reside in enhancers14,36, suggest the dysregulation of enhancer might 
play a role in OA pathogenesis. To further characterize these potentially OA-relevant enhancers, we utilized 
public resources to predict their target genes (Methods). We listed enhancers that overlap OA GWAS SNPs 
(Supplementary Table S4) and OA DML (Supplementary Table S5), as well as their predicted target genes, rep-
resenting candidates of dysregulated transcriptional network during OA pathogenesis. The list includes previ-
ously identified OA associated genes, such as FGFR337,38 (its enhancer overlaps an OA GWAS SNP, Fig. 2b) and 
PTEN39 (its predicted enhancer overlaps with an OA DML, Fig. 2c), thus validating our approach. rs4646626 has 
previously been identified as a suggestive OA risk locus (p = 9 × 10−6,40), for which we found two proxy SNPs 
(rs10851632 and rs12905608), predicted to target the ALDH1A2 gene, hitting the accessible enhancer region 
(chr15:57949887–57950974 and chr15:58021340–58022482, respectively) in our samples. Therefore, our study 
provides an accessible chromatin landscape of cartilage tissue for better interpretation of other genetic and epig-
enomic data relevant to OA and other skeletomuscular disease, although caution should be taken since public 
data from many populations are involved in the integrative analysis while our ATAC-seq dataset is acquired from 
the Japanese population.
Identification of differentially accessible enhancers in OA. To compare the accessible chromatin 
landscape between the intact (oLT) and the damaged (iMT) tissues, we performed principal component analysis 
Figure 2. Identification of accessible chromatin regions with OA susceptible GWAS SNPs and differentially 
methylated loci. (a) Annotation of identified accessible chromatin regions. (b, c) An example of an OA GWAS 
SNP rs11731421 (b) and differentially methylated locus cg09221159 (c) overlapping with an open enhancer in 
cartilages from OA patients. The arrow points to the predicted target genes.
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on the peak signals across the 16 samples. The first principal component (41.37% of variance) can be attributed to 
tissue damage variations (i.e. oLT versus iMT), while the second principal component (16.03% of variance) can 
be attributed to patient-to-patient variations (Fig. 3a). This observation suggests the accessible chromatin land-
scapes of damaged and intact tissues are readily distinguishable from each other, despite the variations among 
individual patients.
To identify the chromatin signatures relevant to OA, we performed differential accessibility analysis between 
oLT and iMT using edgeR41. First and foremost, we assessed the global relevance of the differential accessibility 
of peaks to OA. In Fig. 3b, we investigated the relationship between the extent of differential accessibility of peaks 
(measured by False Discovery Rate (FDR)) and their 1) compositions, 2) enrichment in OA GWAS SNPs, and 3) 
enrichment in OA DML. We found that the peaks that are more differentially accessible (i.e. smaller FDR) contain 
substantially higher fraction of enhancers (Fig. 3b, top panel), suggesting enhancers are more likely to be dysreg-
ulated than promoters during OA disease progression. Moreover, peaks that are more differentially accessible 
Figure 3. Bone- and chondrocyte-specific enhancers are dysregulated in OA cartilage. (a) Principal component 
analysis using ATAC-seq peaks shows general separation between oLT and iMT. (b) Peaks with smaller FDR 
(i.e. more confident to be differentially accessible) are enriched for enhancers (top), OA GWAS SNPs (middle), 
and OA differential methylated loci (DML, bottom). CTL: Control trait (Parkinson’s disease). Circles and error 
bars represent means and 95% confidence intervals for 100 permutations. Shaded grey area represents 0.05–0.95 
percentiles of baseline enrichment by measuring randomly shuffled peaks. (c) Pie chart shows proportions 
of the ATAC-seq peaks that are more accessible in iMT (red) and oLT (blue). (d) Genome browser views of 
example loci (all patients pooled) showing differential accessible regions at promoters (top) and enhancers 
(bottom) with more accessible in iMT (left), more accessible in oLT (middle), and not significantly altered 
between oLT and iMT (right). (e) Enrichment of cell type-specific enhancers in differentially accessible peaks. 
Top 10 are listed (inset), which includes bone- and chondrocyte-related cell types (bold). Error bars represent 
95% confidence interval.
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tend to be more enriched (i.e. higher odds ratio) in both OA GWAS SNPs and DML (Methods, Fig. 3b, middle 
and lower panels). The differentially accessible enhancers (FDR ≤ 0.05) overlapping either OA GWAS SNP (n = 5; 
from 4 independent loci) or OA DML (n = 16, concordant in direction) are summarized in Tables 1 and 2, respec-
tively. We note that 92% of the differentially accessible peaks (FDR ≤ 0.05) overlapping DML are concordant in 
the direction of change (hypomethylation with increased accessibility or hypermethylation with decreased acces-
sibility). As a negative control, we examined the GWAS SNPs and DMLs associated with Parkinson’s disease42, 
which is a neurodegenerative disease pathologically unrelated to cartilage, and did not observe any substantial 
enrichment. Taken together, these observations suggest the differential chromatin accessibility measured in this 
study is relevant to OA disease progression in a specific manner.
We next determined significantly differentially accessible peaks with FDR ≤ 0.05. Out of the 4,450 differ-
entially accessible peaks, 1,565 are more accessible and 2,885 are less accessible in the damaged tissues com-
pared to the intact tissues (Fig. 3c,d, and Supplementary Figure S2a). The identified differentially accessible peaks 
cluster in two groups (Supplementary Figure S2b), and are generally consistent among patients (Supplementary 
Figure S2c). Majority (85.3%) of these differentially accessible peaks are enhancers and only 7.6% are promoters. 
It is noted that the promoter accessibility of SOX11 and RGR are altered in the OA damaged tissues (more acces-
sible for SOX11 and less accessible for RGR, Fig. 3d), which are consistent with the previous findings that they are 
up- and down-regulated in OA damaged tissues, respectively24.
Majority of the differentially accessible peaks are enhancers, which are known to regulate transcription. Cell 
type-specific enhancers largely drive the transcriptional program required to carry out specific functions for each 
cell type43 and their dysregulation may lead to diseases44. To assess the cell type specificity of the differentially 
accessible enhancers identified in this study, we examined their enrichment of cell type-specific enhancers of 125 
cell types defined by the Roadmap Epigenomics Project29. We found these differential accessible enhancers are 
highly enriched for enhancers that are specific to bone-related cell types in damaged tissues (e.g. chondrocyte and 
osteoblast), as well as mesenchymal stem cells (MSC) and fibroblasts, which have been reported to have similar 
profiles to MSC45 (Fig. 3e).
In summary, we demonstrate that the differential accessible chromatin regions identified in this study are 
enriched in OA-relevant enhancers supported by multiple genetic and epigenomic evidence. These differentially 
Enhancer peak ID
Proxy SNP 
ID Lead SNP ID r2
GWAS P 
value Phenotype Population
GWAS 
literature
log2(fold 
change) FDR
Predicted target 
gene(s)
chr7:32611048–32612186 rs10807862 rs7805536 0.8 4.4 × 10−8 OA EUR 40 −0.96 0.01 ZNRF2P1; DPY19L1P1; AVL9; LSM5
chr7:32616344–32617105 rs10951345 rs7805536 0.8 4.4 × 10−8 OA EUR 40 −0.77 0.03 DPY19L1P1; AVL9
chr10:119370132–119371726 rs17098787 rs11198893 0.9 9.0 × 10−6 OA (knee and hip) EUR 87 −0.59 0.02 RP11–215A21.2
chr7:44238166–44238952 rs67391165 rs3757837 1.0 8.0 × 10−10 OA (hip) EUR 88 0.62 0.03 MYL7; YKT6
chr8:125503356–125504061 rs7832357 rs4512391 1.0 1.1 × 10−6 OA (knee and hip) EUR 87 −0.54 0.04 NA
Table 1. Differentially accessible enhancers overlapping with OA GWAS SNPs.
Enhancer peak ID DML Delta beta* Log2 (fold change) FDR Predicted target gene(s)
chr1:19398124–19398841 cg06360604 −0.177 1.194 0.003 AKR7A2; AKR7A3; CAPZB; PQLC2
chr16:66511371–66512170 cg02934719 −0.168 0.827 0.021 BEAN1; TK2
chr11:74025533–74026295 cg01117339 −0.164 0.623 0.037 COA4; RAB6A; UCP2
chr1:85606965–85607684 cg00418071 −0.157 1.214 0.001 CYR61; DDAH1; ZNHIT6; SYDE2
chr4:158809913–158811140 cg11637968 −0.218 0.878 0.032 ETFDH; FAM198B; FNIP2; PPID; C4orf46
chr5:32767956–32768626 cg26647771 −0.198 0.924 0.010 GOLPH3; NPR3; TARS
chr1:226708432–226710048 cg04503570 −0.166 0.500 0.046 PSEN2
chr2:1720779–1722443 cg08216099 −0.193 0.732 0.016 PXDN
chr10:119523073–119524950 cg18591136 −0.152 0.508 0.040 RGS10
chr6:168412123–168412714 cg26379705 −0.174 0.736 0.009 SMOC2
chr6:146850220–146851275 cg18291422 −0.184 0.960 0.012 STXBP5
chr8:81688679–81689538 cg04491064 0.164 −0.959 0.046 CHMP4C
chr12:124700740–124701544 cg04658679 0.160 −0.514 0.030 FAM101A; UBC
chr4:26412447–26413348 cg22992279 0.159 −0.737 0.028 RBPJ
chr11:35344856–35345647 cg13971030 0.157 −0.656 0.038 SLC1A2
chr12:132846887–132848225 cg21232015 0.151 −0.615 0.038 ZNF10; ZNF268; ZNF605; ZNF84; GOLGA3; ANKLE2; CHFR
Table 2. Differentially accessible enhancers overlapping with OA Differentially Methylated Loci. *Positive or 
negative delta beta indicates hypermethylation or hypomethylation in iMT, respectively.
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accessible enhancers and their predicted target genes could be used for prioritization of candidate genes to be 
tested for studying OA disease progression.
Motif enrichment analysis reveals transcription factors relevant to OA. In order to gain more 
insights into which regulatory pathways may be dysregulated in OA, we next examined the enrichment of tran-
scription factor binding motifs in the differentially accessible regions. Enrichment analyses were performed sep-
arately for the regions that are significantly more or less accessible in the damaged tissues, using all accessible 
regions as background. Transcription factors with significantly enriched motifs are summarized (Supplementary 
Figure S3a), and their binding prediction in robust peaks are listed (Supplementary Table S3). We note most of 
these transcription factors belong to ETS and bZIP family; many of which are known to regulate genes involved 
in bone or cartilage development, including AP-146, CEBP47, MafK48, STAT349, and ERG50,51. Moreover, we have 
previously proposed that ETS-1 may be involved in OA based on our DML study25. Taken together, the motif 
enrichment analysis of the differentially accessible regions in the damaged tissues is consistent with the hypoth-
esis that the transcriptional program for chondrocyte differentiation may be disrupted during OA progression, 
and suggests that cell type-specific enhancers may be dysregulated through the ETS and bZIP family transcription 
factors.
Integrative transcriptomics and epigenomics analysis reveals pathways involved in OA. To 
evaluate the effects of the dysregulated regulatory regions on gene expression in OA, we reanalyzed the RNA-seq 
dataset from a different cohort that used the same disease model (i.e. oLT vs. iMT)15 and integrated it with the 
differentially accessible regions identified in this study (Fig. 4a). We first verified that the dysregulated regulatory 
regions have detectable effects on the gene expression; the genes with more accessible promoters or enhancers 
have significantly higher expression fold-changes between oLT and iMT (p < 0.001, Student’s t-test) than the 
ones with less accessible promoters or enhancers (Fig. 4b). To further investigate the congruence between these 
transcriptomic and epigenomic changes, we overlapped the significant differentially expressed genes (n = 3,293, 
FDR ≤ 0.05) onto the genes with differentially accessible promoters (n = 255) or enhancers (n = 2,406) (Fig. 4c). 
We find that their overlaps are statistically significant (p < 0.001 in both promoters and enhancers, Fisher’s exact 
test), which further demonstrate the chromatin accessibility dataset from this study is generally consistent with 
the transcriptomic dataset. As a result, we identified 371 genes that are consistently dysregulated both at the epig-
enomic and transcriptomic levels, representing a shortlist of OA-related candidate genes supported by multiple 
lines of evidence (Fig. 4c, Table 3, Supplementary Table S6).
To elucidate the biological pathways dysregulated in OA, we examined the enrichment of gene ontology (GO) 
terms of the 371 OA-related candidate genes using enrichr52 (Fig. 4d, top 30 terms listed). Overall, we observe 
the enrichment of GO terms related to cell fate and differentiation, including MSC differentiation, ossification 
and bone development (Fig. 4d, dysregulated genes in each GO terms are listed in Supplementary Table S7). In 
the ‘positive regulation of ossification pathway’, two genes were identified to be more accessible and upregulated: 
SOX11 (only the promoter is more accessible) and WNT5A (both the promoter and the enhancer are more acces-
sible) (Supplementary Figure S3b). It has been shown that WNT5A protein can induce matrix metalloproteinase 
production and cartilage destruction53, and its upregulation is consistent with ossification being an important 
process and signature of OA progression. Other susceptible genes and pathways that support the ossification dur-
ing OA from this analysis include LRP5, FGFR2 and BMPR1B in the endochondral bone morphogenesis pathway, 
which have been reported as OA associated genes previously18–20,54–56. In conclusion, our integrative analysis of 
ATAC-seq and publicly available RNA-seq datasets indicates that dysregulated chondrocyte differentiation and 
endochondral ossification are associated with OA progression.
Discussion
Conventional epigenomic profiling at the chromatin level, such as chromatin immunoprecipitation sequencing 
(ChIP-seq) and DNase-seq, is informative in providing insights into the molecular mechanism underlying the 
regulation of gene expression. However, applying these methods to clinically relevant tissue is less feasible due to 
the requirement of large number of cells. Especially with the cartilage tissues, the limited tissue sampling size and 
the extracellular matrix make collection of sufficient cells difficult. One major advantage of ATAC-seq is that it 
can be achieved with only thousands of cells, making the direct chromatin profiling of clinical samples feasible. 
In this study, we applied ATAC-seq on OA samples to obtain a chromatin accessibility map in articular cartilage, 
and identified regulatory regions associated with OA. The lack of normal knee tissues due to difficulties associ-
ated with collecting them is a limitation for studying OA. However, our previous studies of the pathology and 
transcriptome showed that the oLT regions are very similar to normal16,24. Thus, the oLT regions could serve as a 
suitable alternative to normal control, which could also reduce the inter-individual variations.
Our strategy of integrating the epigenomic data of clinically relevant tissues with the publicly available genetic 
and transcriptomic data allowed us to better understand how the identified loci may contribute to OA pathogen-
esis. Most of these accessible chromatin regions are annotated enhancers and we linked them to their putative 
target genes using public datasets. Previous studies have suggested the potential role of OA-associated epigenetic 
changes within enhancers in disease pathogenesis22,23. With this enhancer-gene map in chondrocyte, we can 
now better interpret the previously identified OA GWAS SNPs or OA differential methylated loci located lie 
outside of the coding regions. For example, we have verified 7 OA associated SNPs (rs10851630, rs10851631, 
rs10851632, rs12905608, rs12910752, rs4238326, and rs35246600) reside in 3 chondrocyte accessible enhancers 
of the predicted target gene ALDH1A2 (Supplementary Table S4). Since ALDH1A2 is inactivated in prechondro-
genic mesenchyme during the cartilage development57, these SNPs may contribute to OA through disrupting the 
enhancer of ALDH1A2 and inappropriately activating a cell differentiation pathway. Consistently, OA genetic risk 
variants in ALDH1A2 locus has also been functionally characterized in a recent study58. In addition, we identified 
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Figure 4. Integrative transcriptomic and epigenomic analysis reveals dysregulated genes and pathways in OA. 
(a) A scheme of ATAC-seq and RNA-seq integration analysis. (b) Differential chromatin accessibility (ATAC-
seq) at both promoter (left) and enhancer (right) in OA is generally consistent with differential expression 
(RNA-seq). Fold change between iMT and oLT is plotted. Box plots show the median, quartiles, and Tukey 
whiskers. (c) Venn diagram summarizing protein coding genes that are dysregulated both at the transcriptomic 
(RNA-seq) and epigenomic (ATAC-seq) levels in OA with concordant direction of change. (d) GO enrichment 
analysis of 371 genes from (c). Top 30 terms in GO biological process ranked by the level of enrichment and 
overlapping dysregulated genes are listed. Terms related to MSC, bones, and chondrocytes are highlight in bold.
www.nature.com/scientificreports/
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several aberrantly methylated enhancers that may be associated with OA. One example is cg09221159 within the 
enhancer for PTEN gene which is hypomethylated in the damaged cartilage25. PTEN is involved in the positive 
regulation of the apoptotic signaling pathway and its activation is consistent with the notion that chondrocyte 
apoptosis may contribute to the failure in appropriately maintaining the cartilage. Thus, our analyses show that 
the chromatin accessibility map can provide an additional layer of evidence for determining which loci, especially 
those in the non-coding regions, are associated with OA, which may have been ignored in previous studies.
In general, our differential enhancer analysis shows MSC, chondrocyte and osteoblast-specific enhancers 
are dysregulated in the damaged tissues. Furthermore, motif enrichment analysis of differentially accessible loci 
has identified many dysregulated transcription factors, the functions of which are known to be in chondrocyte 
development regulation. For example, the transcription factor Jun-AP1, which is enriched in the more accessible 
regions of the damaged tissues, is known to regulate chondrocyte hypertrophic morphology, which contributes to 
longitudinal bone growth, consistent with the notion of endochondral ossification59. A recent study showed injec-
tion of adipose-derived stromal cells overexpressing an AP-1 family transcription factor Fra-1 can inhibit OA 
progression in mice60. Consistently, in our ATAC-seq analysis, other members of AP-1 family (e.g. BATF, FOSL2) 
also showed enrichment in differentially accessible regions. In addition, if we combine the RNA-seq data15, 15 out 
of 18 transcription factor genes identified in the motif analysis are expressed (CPM ≥ 2) in the cartilage tissue, 
of which ETS1 is differentially expressed between the two cartilage types. These transcription factors could be 
candidate targets for further experiments.
In the integrative analysis of ATAC-seq and RNA-seq, many dysregulated genes related to lineage differentia-
tion of MSC pathways were observed. For example, we found that BMPR1B (bone morphogenetic protein recep-
tor type 1B) is upregulated and both its promoter and enhancer are more accessible in the damaged tissue. Its 
activation is consistent with the ossification pathway activation, since it encodes a transmembrane serine kinase 
that binds to BMP ligands that positively regulate endochondral ossification and abnormal chondrogenesis61,62. 
Consistently, an osteoblast marker gene MSX2 (Msh Homeobox 2) involved in promoting osteoblast differentia-
tion63,64, is upregulated and both its promoter and enhancer are more accessible in the damaged tissue, suggesting 
the osteoblast differentiation may be activated in OA. Furthermore, we found ROR2 (receptor tyrosine kinase 
like orphan receptor 2) is down-regulated and its enhancers are less accessible in the damaged samples. Since it 
is required for cartilage development65,66, it suggests that the normal chondrocyte development and cartilage for-
mation may be compromised in OA. Consistently, we have also determined FGFR2 and STAT1, which are known 
Genes
Differentially 
expressed
Differentially 
accessible promoter
Differentially 
accessible enhancer
BMPR1B √ √ √
WNT5A √ √ √
ZMIZ1 √ √
CHRD √ √
DCC √ √
HMGA2 √ √
PMAIP1 √ √
PRDM1 √ √
SOX11 √ √
TENM3 √ √
WNT5B √ √
BDNF √ √
CHDH √ √
ETS1 √ √
FGFR2 √ √
FOXF1 √ √
IFT122 √ √
LRP5 √ √
MAF √ √
PTPRS √ √
RPS19 √ √
RTN4RL1 √ √
SLC2A12 √ √
SLC2A5 √ √
SLC44A1 √ √
TBX4 √ √
THBS1 √ √
ZNF516 √ √
Table 3. OA associated genes enriched in top 30 GO terms.
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to inhibit chondrocyte proliferation67, are upregulated. In summary, our ATAC-seq data and integrative analyses 
support the OA model of abnormal MSC differentiation and endochondral ossification over other models, such 
as inflammatory mediums from the synovium.
The pathogenesis for OA is not yet fully understood, despite multiple genes and pathways that have been 
characterized to be dysregulated13,15,68–70. In this study, by integrating clinically relevant epigenomic data with 
genetic and transcriptomic data, we provide multiple lines of evidence supporting a number OA candidate genes 
and pathways that may be crucial to OA pathogenesis, which could potentially be used for clinical diagnostic or 
as therapeutic targets.
Conclusions
We present in this work an application of ATAC-seq in OA in a clinical relevant setting. The chromatin acces-
sibility map in cartilage will be a resource for future GWAS and DNA methylation studies in OA and other 
musculoskeletal diseases. We identified altered promoters and enhancers of genes that might be involved in the 
pathogenesis of OA. Our analyses suggest aberrant enhancer usage associated with MSC differentiation and chon-
drogenesis in OA. Understanding these molecular basis of OA is necessary for future therapeutic intervention.
Methods
Knee joint tissues collection. Human knee joint tibial plates were collected from patients who undertook 
joint replacement surgery due to severe primary OA at the National Hospital Organization Sagamihara Hospital 
(Kanagawa, Japan). Demographic information for patients is listed in Supplementary Table S1. Diagnosis of OA 
was based on the criteria of the American College of Rheumatology71, and all the knees were medially involved 
in the disease. Tissues were stored in 4 °C Dulbecco’s Modified Eagle Medium (DMEM) after removal for less 
than one hour prior to cartilage sectioning. Informed consent was obtained from each patient enrolled in this 
study. This study was approved by the institutional review board of all the participating institutions (Sagamihara 
National Hospital and RIKEN).
Processing of cartilage samples. Fresh cartilage was separated from the subchondral bone by a scal-
pel after surgery and stored in 4 °C DMEM for three hours until they were processed. 100 mg cartilage from 
both outer region of lateral tibial plateau (oLT) and inner region of medial tibial plateau (iMT) (Fig. 1a and 
Supplementary Figure S1a) for each patient was digested with 0.2% type II collagenase (Sigma-Aldrich) in 
DMEM at 37 °C with rotation for 12 hours to fully remove the collagen matrix debris, and stopped by washing 
with chilled PBS. Immediately after digestion, chondrocytes were counted by a cell counting chamber Incyto 
C-Chip (VWR) and collected by centrifugation at 500 g for 5 minutes at 4 °C.
ATAC-seq of the cartilage. Approximately 50,000 cells were taken after the cartilage processing and used 
for ATAC-seq library preparation (Fig. 1a) according to the original protocol32,72. Briefly, transposase reaction was 
carried out as previously described32 followed by 9 to 12 cycles of PCR amplification. Amplified DNA fragments 
were purified with MinElute PCR Purification Kit (QIAGEN) and size selected twice with Agencourt AMPure XP 
(1:1.5 and 1:0.5 sample to beads; Beckman Coulter). Libraries were quantified by KAPA Library Quantification 
Kit for Illumina Sequencing Platforms (KAPA Biosystems), and size distribution was inspected by Bioanalyzer 
(Agilent High Sensitivity DNA chip, Agilent Technologies). Library quality was assessed before sequencing by 
qPCR enrichment of a housekeeping gene promoter (GAPDH) over a gene desert region72. ATAC-seq libraries 
were sequenced on an Illumina HiSeq 2500 (50 bp, paired-end) by GeNAS (Genome Network Analysis Support 
Facility, RIKEN, Yokohama, Japan).
ATAC-seq data processing, peak calling and quality assessment. An ATAC-seq data process-
ing pipeline for read mapping, peak calling, signal track generation, and quality control was implemented73. 
Briefly, fastq files for all patients were grouped by tissue compartment (oLT or iMT) and input into the pipeline 
separately, with parameters –true_rep –no_idr. Reads were mapped to the hg38 reference genome. Peaks for 
individual samples, as well as for pooled oLT and pooled iMT, were called by MACS2 with default parameters 
in the pipeline. Basic sequencing information and library quality metrics are listed in Supplementary Table S2. 
NucleoATAC was applied to infer genome-wide nucleosome positions and occupancy from the ATAC-seq data35. 
Briefly, NucleoATAC were run for oLT and iMT separately with default parameters, using bam files merging from 
all patients as input, and the outputted nucleoatac_signal.bedgraph were used for aggregated plot around TSS.
Previously annotated DNase I Hypersensitive Sites (DHS) were used to assess the quality of our libraries. 
Briefly, a set of DHS defined in Roadmap Epigenomics Project74 were downloaded (http://egg2.wustl.edu/
roadmap/web_portal/DNase_reg.html) and lifted over from hg19 to hg38 using UCSC liftOver tool75 (refer as 
Roadmap DHS thereafter). For each library, we calculated the ratio of reads that fall within Roadmap DHS versus 
randomly chosen genomic regions of the same total size (DHS enrichment score). It is noted that the DHS enrich-
ment score is in good correlation with enrichment qPCR for GAPDH (Supplementary Figure S1b).
Defining a set of unified accessible chromatin regions. Peaks called from pooled oLT and pooled iMT 
were merged as raw peak regions using bedtools v2.27.076 (mergeBed -d 300). Reads fall in raw peak regions were 
counted for individual samples using bedtools76. Read counts were normalized as count-per-million (CPM) based 
on relative log expression normalization (RLE) method implemented in edgeR v3.18.141,77. In the end, we defined 
a set robust peaks (n = 109,215) with ≥2 CPM in at least 6 oLT or 6 iMT samples for all downstream analyses.
Peak annotation and differentially accessible peak identification. Peaks were annotated as promot-
ers or enhancers based on their intersection with promoter or enhancer as defined in Roadmap DHS29. Noted that 
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a peak was preferentially annotated as a promoter if it intersects both a promoter and a proximal enhancer DHS 
(n = 1,693. 1.6% of total robust peaks). Differentially accessible peaks between damaged (i.e. iMT) and intact (i.e. 
oLT) tissues were identified using edgeR41,77. Briefly, read counts were normalized by the effective library size 
with the RLE method and DHS enrichment score of each sample were incorporated as continuous covariates in 
the design matrix of the generalized linear model implemented in edgeR41,77. The Benjamini-Hochberg adjusted 
p-values (i.e. false discovery rate, FDR) was taken to measure the extent of differential accessibility as used in 
Fig. 3b. A cutoff of FDR ≤ 0.05 was used to define differentially accessible peaks.
Processing of trait associated SNPs and DMLs. GWAS lead SNPs of all phenotypes of OA with 
genome-wide significance p ≤ 1 × 10−5 were obtained from GWASdb v2 (as of 20 Jun 2018)78, NHGRI-EBI 
GWAS Catalog (as of 20 Jun 2018)79, and a recent study80, totaling 197 lead SNPs. SNPs in linkage disequilibrium 
(LD) with these lead SNPs in matched populations (i.e. proxy SNPs, with r2 ≥ 0.8 within of 500 kb) were searched 
using PLNK v1.90b5.4 (https://www.cog-genomics.org/plink2), based on the 1000 Genomes Project Phase 3 data 
obtained from MAGMA81. It results in 4,483 GWAS SNPs associated with OA, consisting of 167 independent loci 
with non-overlapping LD blocks. As a negative control, GWAS SNPs associated with Parkinson’s disease were 
obtained in the same manner. Coordinates for these SNPs in hg38 were obtained from dbSNP Build 150.
Differentially methylated loci associated with OA were obtained from previous studies25,70 and all identified 
DML were pooled and mapped to hg38 (n = 9,265). Parkinson’s disease associated DMLs as a negative control 
trait were obtained from a previous study42.
Definition of cell type-specific enhancers. Bed files for enhancer clusters with coordinated activity in 
127 epigenomes, as well as the density of clusters per cell type, were obtained from online database (http://egg2.
wustl.edu/roadmap/web_portal/DNase_reg.html). DNase I regions selected with p < 1 × 10−2, lifted over from 
hg19 to hg38 using UCSC liftOver tool. For each cell type, clusters with two-fold density than average (across all 
cell types) were defined as specific and pooled.
Enrichment analysis for differentially accessible peaks. The enrichment of GWAS SNPs and DML in 
differentially accessible peaks were assessed as described in previous studies82,83. Briefly, trait associated (i.e. OA 
and Parkinson’s disease) SNPs (i.e. lead and proxy SNPs) and DMLs are referred to as foreground positions. For 
SNPs, ten millions of randomly selected common SNPs in dbSNP Build 150 were used to define the background 
positions. For DML, all probes in Illumina Infinium HumanMethylation450K were used as the background posi-
tions. Enrichment of foreground SNPs/DML in each set of regions (i.e. differentially accessible peaks at various 
FDR cutoffs) was evaluated by first counting the number of the foreground and background positions intersecting 
these regions (refer as observedfore and observedback). The counting was repeated for 100 rounds of permutation, 
i.e. regions of the same number and sizes shuffled into the masked genomic regions using bedtools shuffle76 (refer 
as shuffledfore and shuffledback). Masked genomic regions was defined as the whole genome excluding the anno-
tated gaps. Only the 22 autosomes were included in analyses. The odds ratio of foreground signal enrichment for 
each round of permutation was calculated as (observedfore/observedback)/(shuffledfore/shuffledback). As a negative 
control, for the trait, the analyses were repeated by replacing the foreground SNPs and DML with those associated 
with Parkinson’s disease.
In Fig. 3e, the enrichment of cell type-specific enhancers in differentially accessible peaks (FDR ≤0.05) were 
assessed by Fisher’s exact test. Same number of peaks were randomly sampled from all robust peaks as controls.
Linking enhancer peaks to their potential target genes. A promoter peak was assigned to a gene if it 
intersected with the transcription start sites (TSS) of its transcript as defined in the FANTOM CAGE associated 
transcriptome82. We note that a promoter peak might be associated with multiple genes. An enhancer peak was 
defined as linked to a target gene if it overlapped an expression quantitative trait loci (eQTL) of the corresponding 
gene (GTEx V7, in any tissues with p < 1 × 10−5)84, or is supported by putative enhancer-promoter linkage pre-
dicted by JEME method (http://yiplab.cse.cuhk.edu.hk/jeme/based) on FANTOM5 and Roadmap Epigenomics 
Project data31. Out of the 77,655 enhancer peaks, 36,228 of them were linked to at least one gene, of which 15,391 
(42.5%) were assigned to one gene, 8,073 (22.3%) to two genes, and 12,764 (35.2%) to three or more genes.
Integration with publicly available transcriptome data. We reanalyzed an RNA-seq dataset 
(ArrayExpress E-MTAB-4304) from an independent OA patient cohort, in which the RNA was extracted from 
cartilage tissues of both iMT and oLT for 8 patients15. Read counts on transcripts were estimated by Kallisto 
v0.43.185 using default parameters on FANTOM CAGE associated transcriptome82. Estimated read counts of 
a gene, defined as the sum of the estimated read counts of its associated transcripts, were used as the input for 
differential gene expression analysis using edgeR v3.18.1. In total, 3,293 genes were defined as significantly differ-
entially expressed between iMT and oLT (FDR ≤ 0.05). A gene is defined as “consistently dysregulated both at the 
epigenomic and transcriptomic levels” when it is upregulated (or downregulated) in RNA-seq with more (or less) 
accessible promoters or enhancers in ATAC-seq (n = 371).
Gene ontology analysis. Enrichr52 was used to identify gene sets enriched in genes implicated in OA. The 
selected gene lists were input to query enrichment for gene ontology (Biological Process 2017b) in the database. 
Terms with p-value ≤ 0.05 and FDR ≤0.25 were considered significant (n = 421 of 4437). Top 30 terms ranked by 
percentage of overrepresented genes are listed in Fig. 4d. All terms are listed in Supplementary Table S7. It is of 
note that terms with fewer number of genes tend to rank higher in this way.
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Transcription factor binding motif analysis. DNA motif analysis for differentially accessible regions was 
performed using HOMER v4.9 with default parameters86. The enriched de novo and known motifs as well as its 
matching transcription factor are searched and scanned in more- and less-accessible peaks separately (parame-
ters: -mask -size given), with all robust peaks as background region. P-value < 1 × 10−5 was considered significant.
Ethics, consent and permissions. This study was approved by the ethics review board of all the participat-
ing institutions (Sagamihara National Hospital and RIKEN) and all experiments were carried out in accordance 
with their guidelines and regulations.
Consent to publish. Informed consent was obtained from each patient enrolled in this study.
Availability of Data and Materials
Raw and processed data generated are available on the Gene Expression Omnibus under the accession code 
GSE108301.
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